Adderall is a central nervous system stimulant classified as a Schedule II drug by the Drug Enforcement Administration (DEA) and the US Food and Drug Administration (FDA) due to its high potential for abuse. Both immediate-release and sustained-release amphetamine medications are FDA-approved for treating attention-deficit hyperactivity disorder (ADHD) and narcolepsy in adult and pediatric populations. The drug works by increasing dopamine and norepinephrine levels through catecholamine release and reuptake inhibition. Off-label uses of dextroamphetamine-amphetamine include the management of cerebrovascular accidents.This activity provides healthcare professionals with essential knowledge and tools to effectively tailor treatments to individual patient needs. In addition, this activity emphasizes the importance of collaboration among the interprofessional healthcare team in delivering evidence-based care to optimize patient outcomes in dextroamphetamine-amphetamine therapy.
